Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
- 10 September 2015
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 38 (11) , 2142-2150
Abstract
OBJECTIVE Patients with type 2 diabetes have an increased risk of bone fractures, the predisposing factors for which are unknown. Treatment with thiazolidinediones (TZDs) further increases the incidence of osteoporotic fractures. In the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction 53 (SAVOR-TIMI 53) trial, fractures were considered an adverse event of special interest, and information regarding fractures was collected. RESEARCH DESIGN AND METHODS We compared the incidence of fractures among the 8,280 patients who were assigned to treatment with saxagliptin with that in the 8,212 patients who were assigned to placebo. We further analyzed the participants’ baseline characteristics and fracture risk. RESULTS During a median follow-up of 2.1 years, 241 patients (2.9%) in the saxagliptin group and 240 (2.9%) in the placebo group experienced a fracture (hazard ratio [HR] 1.00 [95% CI 0.83–1.19]). Event rates for fractures were the same in both treatment arms: 14.7 per 1,000 patient-years in the entire population and 14.0 in the on-treatment population (first event only). Fracture risk was similar in patients treated with saxagliptin or placebo across different subgroups defined by race, cardiovascular risk, and renal function. A multivariable Cox regression analysis showed that risk of fracture was associated with female sex (P < 0.0001), longer diabetes duration (P < 0.0001), older age (P = 0.002), major hypoglycemic events (P = 0.01), noncompliance with study drug (P = 0.01), and treatment with TZDs (P = 0.03). CONCLUSIONS In a large population of older patients with type 2 diabetes, treatment with saxagliptin was not associated with an increased risk of fractures. The association between longer diabetes duration and increased risk of bone fracture is an intriguing finding.Keywords
Funding Information
- AstraZeneca
This publication has 40 references indexed in Scilit:
- Dipeptidyl Peptidase-4 Inhibitors and Bone FracturesDiabetes Care, 2011
- Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 DiabetesJAMA, 2011
- Exenatide treatment did not affect bone mineral density despite body weight reduction in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2011
- Insulin Signaling in Osteoblasts Integrates Bone Remodeling and Energy MetabolismCell, 2010
- Diabetes and Risk of Hip Fracture in the Singapore Chinese Health StudyDiabetes Care, 2010
- Diabetic Patients Have an Increased Risk of Vertebral Fractures Independent of BMD or Diabetic ComplicationsJournal of Bone and Mineral Research, 2009
- Fracture Risk in Type 2 Diabetes: Update of a Population-Based StudyJournal of Bone and Mineral Research, 2008
- Relationships between fat and boneOsteoporosis International, 2007
- Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic MenDiabetes Care, 2007
- Nontraumatic Fracture Risk With Diabetes Mellitus and Impaired Fasting Glucose in Older White and Black AdultsArchives of internal medicine (1960), 2005